-
1
-
-
84966283006
-
-
Accessed 31 Mar 2016
-
European Medicines Agency. Guideline on similar biological medicinal products. 2014. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2014/10/WC500176768.pdf. Accessed 31 Mar 2016.
-
(2014)
Guideline on similar biological medicinal products
-
-
-
2
-
-
84942234810
-
Scientific considerations in demonstrating biosimilarity to a reference product
-
United States Food and Drug Administration. Scientific considerations in demonstrating biosimilarity to a reference product. Guidance for industry. 2015. http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/UCM291128.pdf. Accessed 31 Mar 2016.
-
(2015)
Guidance for industry
-
-
Food, U.S.1
Administration, D.2
-
3
-
-
78049362302
-
-
Accessed 31 Mar 2016
-
World Health Organization. Guidelines on evaluation of similar biotherapeutic products (SBPs). 2010. http://www.who.int/biologicals/areas/biological_therapeutics/BIOTHERAPEUTICS_FOR_WEB_22APRIL2010.pdf. Accessed 31 Mar 2016.
-
(2010)
Guidelines on evaluation of similar biotherapeutic products (SBPs)
-
-
-
4
-
-
84863435547
-
The advent of biosimilar therapies in rheumatology–“O Brave New World
-
Scheinberg MA, Kay J. The advent of biosimilar therapies in rheumatology–“O Brave New World”. Nat Rev Rheumatol. 2012;8:430–6.
-
(2012)
Nat Rev Rheumatol
, vol.8
, pp. 430-436
-
-
Scheinberg, M.A.1
Kay, J.2
-
5
-
-
84964262382
-
Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology
-
COI: 1:CAS:528:DC%2BC28XjslOqtrc%3D, PID: 26920148
-
Mysler E, Pineda C, Horiuchi T, Singh E, Mahgoub E, Coindreau J, et al. Clinical and regulatory perspectives on biosimilar therapies and intended copies of biologics in rheumatology. Rheumatol Int. 2016;36:613–25. doi:10.1007/s00296-016-3444-0.
-
(2016)
Rheumatol Int
, vol.36
, pp. 613-625
-
-
Mysler, E.1
Pineda, C.2
Horiuchi, T.3
Singh, E.4
Mahgoub, E.5
Coindreau, J.6
-
8
-
-
84948714780
-
Biosimilars in rheumatology: current perspectives and lessons learnt
-
PID: 26282080
-
Dorner T, Kay J. Biosimilars in rheumatology: current perspectives and lessons learnt. Nat Rev Rheumatol. 2015;11:713–24. doi:10.1038/nrrheum.2015.110.
-
(2015)
Nat Rev Rheumatol
, vol.11
, pp. 713-724
-
-
Dorner, T.1
Kay, J.2
-
9
-
-
84969996341
-
Interchangeability. An insurmountable fifth hurdle?
-
Ebbers HC, Chamberlain P. Interchangeability. An insurmountable fifth hurdle? GaBI J. 2014;3:88–93. doi:10.5639/gabij.2014.0302.022.
-
(2014)
GaBI J
, vol.3
, pp. 88-93
-
-
Ebbers, H.C.1
Chamberlain, P.2
-
10
-
-
84872423673
-
On the interchangeability of biologic drug products
-
PID: 22911936
-
Endrenyi L, Chang C, Chow SC, Tothfalusi L. On the interchangeability of biologic drug products. Stat Med. 2013;32:434–41. doi:10.1002/sim.5569.
-
(2013)
Stat Med
, vol.32
, pp. 434-441
-
-
Endrenyi, L.1
Chang, C.2
Chow, S.C.3
Tothfalusi, L.4
-
11
-
-
84944325199
-
Clinical trial development for biosimilars
-
PID: 26058550
-
Alten R, Cronstein BN. Clinical trial development for biosimilars. Semin Arthritis Rheum. 2015;44:S2–8. doi:10.1016/j.semarthrit.2015.04.002.
-
(2015)
Semin Arthritis Rheum
, vol.44
, pp. S2-S8
-
-
Alten, R.1
Cronstein, B.N.2
-
12
-
-
84960851952
-
The changing landscape of biosimilars in rheumatology
-
Dorner T, Strand V, Cornes P, Goncalves J, Gulacsi L, Kay J, et al. The changing landscape of biosimilars in rheumatology. Ann Rheum Dis. 2016;75:974–82. doi:10.1136/annrheumdis-2016-209166.
-
(2016)
Ann Rheum Dis
, vol.75
, pp. 974-982
-
-
Dorner, T.1
Strand, V.2
Cornes, P.3
Goncalves, J.4
Gulacsi, L.5
Kay, J.6
-
13
-
-
84994430918
-
The design of clinical trials to support the switching and alternation of biosimilars
-
Faccin F, Tebbey P, Alexander E, Wang X, Cui L, Albuquerque T. The design of clinical trials to support the switching and alternation of biosimilars. Expert Opin Biol Ther. 2016;16:1445–53.
-
(2016)
Expert Opin Biol Ther
, vol.16
, pp. 1445-1453
-
-
Faccin, F.1
Tebbey, P.2
Alexander, E.3
Wang, X.4
Cui, L.5
Albuquerque, T.6
-
14
-
-
0008348082
-
-
Accessed 31 Oct
-
European Medicines Agency. European public assessment reports (biosimilars). http://www.ema.europa.eu/ema/index.jsp?curl=pages%2Fmedicines%2Flanding%2Fepar_search.jsp&mid=WC0b01ac058001d124&searchTab=searchByAuthType&alreadyLoaded=true&isNewQuery=true&status=Authorised&status=Withdrawn&status=Suspended&status=Refused&keyword=Enter+keywords&searchType=name&taxonomyPath=&treeNumber=&searchGenericType=biosimilars&genericsKeywordSearch=Submit. Accessed 31 Oct 2016.
-
(2016)
European public assessment reports (biosimilars)
-
-
-
15
-
-
85021229415
-
-
Accessed 31 Oct 2016
-
United States Food and Drug Administration. Center for drug evaluation and research list of licensed biological products. 2016. http://www.fda.gov/downloads/Drugs/DevelopmentApprovalProcess/HowDrugsareDevelopedandApproved/ApprovalApplications/TherapeuticBiologicApplications/Biosimilars/UCM439049.pdf. Accessed 31 Oct 2016.
-
(2016)
Center for drug evaluation and research list of licensed biological products
-
-
-
19
-
-
85021227371
-
-
Accessed 28 Feb
-
European Medicines Agency. Human medicines: pending EC decisions: Amgevita. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004212/smops/Positive/human_smop_001091.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 28 Feb 2017.
-
(2017)
Human medicines: pending EC decisions: Amgevita
-
-
-
20
-
-
85021227371
-
-
Accessed 28 Feb
-
European Medicines Agency. Human medicines: pending EC decisions: Solymbic. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/004373/smops/Positive/human_smop_001092.jsp&mid=WC0b01ac058001d127&source=homeMedSearch&category=human. Accessed 28 Feb 2017.
-
(2017)
Human medicines: pending EC decisions: Solymbic
-
-
-
21
-
-
85021202207
-
SB5, an adalimumab biosimilar referencing Humira®
-
Biogen. SB5, an adalimumab biosimilar referencing Humira®, accepted for review by European Medicines Agency. 2016. http://media.biogen.com/press-release/biosimilars/sb5-adalimumab-biosimilar-referencing-humira-accepted-review-european-medi. Accessed 31 Oct 2016.
-
(2016)
accepted for review by European Medicines Agency
-
-
-
22
-
-
85021220682
-
-
Accessed 31 Oct 2016
-
Generics and Biosimilars Initiative. Celltrion submits rituximab biosimilar application to EMA. 2015. http://www.gabionline.net/Biosimilars/News/Celltrion-submits-rituximab-biosimilar-application-to-EMA. Accessed 31 Oct 2016. doi:10.3402/ijch.v74.27284.
-
(2015)
Celltrion submits rituximab biosimilar application to EMA
-
-
-
24
-
-
85021232355
-
Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13
-
San Diego, California, USA
-
Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with rheumatoid arthritis: comparison between continued CT-P13 and switching from infliximab to CT-P13. American College of Rheumatology 2013; San Diego, California, USA: 2013.
-
(2013)
American College of Rheumatology
, vol.2013
-
-
Yoo, D.H.1
Prodanovic, N.2
Jaworski, J.3
Miranda, P.4
Ramiterre, E.5
Lanzon, A.6
-
25
-
-
84966417145
-
Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
-
PID: 27130908, This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with rheumatoid arthritis, and specifically compares clinical data before and after switching
-
• Yoo DH, Prodanovic N, Jaworski J, Miranda P, Ramiterre E, Lanzon A, et al. Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study. Ann Rheum Dis. 2017;76:355–63. doi:10.1136/annrheumdis-2015-208786. This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with rheumatoid arthritis, and specifically compares clinical data before and after switching.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 355-363
-
-
Yoo, D.H.1
Prodanovic, N.2
Jaworski, J.3
Miranda, P.4
Ramiterre, E.5
Lanzon, A.6
-
26
-
-
84970012234
-
Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13
-
San Diego, California, USA
-
Park W, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, Mikazane H, et al. Efficacy and safety of CT-P13 (infliximab biosimilar) over two years in patients with ankylosing spondylitis: comparison between continuing with CT-P13 and switching from infliximab to CT-P13. American College of Rheumatology 2013; San Diego, California, USA: 2013.
-
(2013)
American College of Rheumatology
, vol.2013
-
-
Park, W.1
Miranda, P.2
Brzosko, M.3
Wiland, P.4
Gutierrez-Ureña, S.5
Mikazane, H.6
-
27
-
-
84965014483
-
Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study
-
PID: 27117698, This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with ankylosing spondylitis, and specifically compares clinical data before and after switching
-
• Park W, Yoo DH, Miranda P, Brzosko M, Wiland P, Gutierrez-Ureña S, et al. Efficacy and safety of switching from reference infliximab to CT-P13 compared with maintenance of CT-P13 in ankylosing spondylitis: 102-week data from the PLANETAS extension study. Ann Rheum Dis. 2017;76:346–54. doi:10.1136/annrheumdis-2015-208783. This study is the largest study of switching from infliximab to CT-P13 exclusively in patients with ankylosing spondylitis, and specifically compares clinical data before and after switching.
-
(2017)
Ann Rheum Dis
, vol.76
, pp. 346-354
-
-
Park, W.1
Yoo, D.H.2
Miranda, P.3
Brzosko, M.4
Wiland, P.5
Gutierrez-Ureña, S.6
-
28
-
-
84984714652
-
Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab
-
Tanaka Y, Yamanaka H, Takeuchi T, Inoue M, Saito K, Saeki Y, et al. Safety and efficacy of CT-P13 in Japanese patients with rheumatoid arthritis in an extension phase or after switching from infliximab. Mod Rheumatol. 2017;27:237-45.
-
(2017)
Mod Rheumatol
, vol.27
, pp. 237-245
-
-
Tanaka, Y.1
Yamanaka, H.2
Takeuchi, T.3
Inoue, M.4
Saito, K.5
Saeki, Y.6
-
29
-
-
85021197245
-
A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab
-
Washington DC, USA: Arthritis Rheumatol, Accessed 17 May 2017
-
Yazici Y, Xie L, Ogbomo A, Parenti D, Goyal K, Teeple A, et al. A descriptive analysis of real-world treatment patterns in a Turkish rheumatology population that continued innovator infliximab (Remicade) therapy or switched to biosimilar infliximab. American College of Rheumatology; 2016 Washington DC, USA: Arthritis Rheumatol. 2016;68 (suppl10). http://acrabstracts.org/abstract/a-descriptive-analysis-of-real-world-treatment-patterns-in-a-turkish-rheumatology-population-that-continued-innovator-infliximab-remicade-therapy-or-switched-to-biosimilar-infliximab/ Accessed 17 May 2017.
-
(2016)
American College of Rheumatology
, vol.68
-
-
Yazici, Y.1
Xie, L.2
Ogbomo, A.3
Parenti, D.4
Goyal, K.5
Teeple, A.6
-
30
-
-
85021204246
-
-
Scandinavian Congress of Rheumatology, Reykjavik: The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early clinical data on the efficacy of switching
-
• Glintborg B, Sørensen IJ, Jensen DV, Krogh NS, Loft AG, Colic A, et al. Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry. Scandinavian Congress of Rheumatology; Reykjavik: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early clinical data on the efficacy of switching.
-
(2016)
Three months’ clinical outcomes from a nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Results from the DANBIO registry
-
-
Glintborg, B.1
Sørensen, I.J.2
Jensen, D.V.3
Krogh, N.S.4
Loft, A.G.5
Colic, A.6
-
31
-
-
85021195497
-
Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry
-
The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effect of switching
-
• Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis: impact on s-infliximab and antidrug antibodies. Results from the Danish Rheumatological Biobank and the DANBIO registry. Scandinavian Congress of Rheumatology; Reykjavik: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effect of switching.
-
(2016)
Scandinavian Congress of Rheumatology; Reykjavik
-
-
Glintborg, B.1
Kringelbach, T.2
Høgdall, E.3
Sørensen, I.J.4
Jensen, D.V.5
Loft, A.G.6
-
32
-
-
85021246962
-
Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease–impact on s-infliximab and anti-drug antibodies. Results from the National Danish Rheumatologic Biobank and the DANBIO registry
-
London, UK; Ann Rheum Dis: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effects of switching
-
• Glintborg B, Kringelbach T, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab among patients with inflammatory rheumatic disease–impact on s-infliximab and anti-drug antibodies. Results from the National Danish Rheumatologic Biobank and the DANBIO registry. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important early immunogenicity data on the effects of switching.
-
(2016)
European League Against Rheumatism
-
-
Glintborg, B.1
Kringelbach, T.2
Høgdall, E.3
Sørensen, I.J.4
Jensen, D.V.5
Loft, A.G.6
-
33
-
-
85021222436
-
A nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Eleven months’ clinical outcomes from the Danbio Registry
-
Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term clinical data on the efficacy and safety of switching
-
• Glintborg B, Sørensen IJ, Jensen DV, Krogh NS, Loft AG, Espesen J, et al. A nationwide non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis. Eleven months’ clinical outcomes from the Danbio Registry. American College of Rheumatology 2016; Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term clinical data on the efficacy and safety of switching.
-
(2016)
American College of Rheumatology
-
-
Glintborg, B.1
Sørensen, I.J.2
Jensen, D.V.3
Krogh, N.S.4
Loft, A.G.5
Espesen, J.6
-
34
-
-
85021192993
-
Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis—impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry
-
Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term immunogenicity data on the effects of switching
-
• Glintborg B, Kringelbach TM, Høgdall E, Sørensen IJ, Jensen DV, Loft AG, et al. Non-medical switch from originator to biosimilar infliximab in patients with inflammatory arthritis—impact on s-infliximab and antidrug-antibodies. Results from the Danish Rheumatologic Biobank and the Danbio Registry. American College of Rheumatology 2016; Washington DC, USA: 2016. The DANBIO registry analysis is the largest real-world study of the effects of switching from infliximab to CT-P13 in patients with rheumatic disease to date. This publication provides important longer-term immunogenicity data on the effects of switching.
-
(2016)
American College of Rheumatology
-
-
Glintborg, B.1
Kringelbach, T.M.2
Høgdall, E.3
Sørensen, I.J.4
Jensen, D.V.5
Loft, A.G.6
-
35
-
-
85026616778
-
Switching to biosimilar infliximab: real-world data from the Southampton biologic therapies review service
-
Annual Meeting; Glasgow, UK; Rheumatology (Oxford
-
Holroyd C, Parker L, Bennett S, Zarroug J, Underhill C, Davidson B, et al. Switching to biosimilar infliximab: real-world data from the Southampton biologic therapies review service. British Society for Rheumatology 2016 Annual Meeting; Glasgow, UK; Rheumatology (Oxford): 2016. doi:10.1093/rheumatology/kew121.003.
-
(2016)
British Society for Rheumatology
, vol.2016
-
-
Holroyd, C.1
Parker, L.2
Bennett, S.3
Zarroug, J.4
Underhill, C.5
Davidson, B.6
-
36
-
-
84979496968
-
Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study
-
Benucci M, Gobbi FL, Bandinelli F, Damiani A, Infantino M, Grossi V, et al. Safety, efficacy and immunogenicity of switching from innovator to biosimilar infliximab in patients with spondyloarthritis: a 6-month real-life observational study. Immunol Res. 2016:1–4. doi:10.1007/s12026-016-8843-5.
-
(2016)
Immunol Res
, pp. 1-4
-
-
Benucci, M.1
Gobbi, F.L.2
Bandinelli, F.3
Damiani, A.4
Infantino, M.5
Grossi, V.6
-
37
-
-
85021240324
-
Safety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational study
-
London: UK; Ann Rheum Dis
-
Batticciotto A, Parisi S, Gobbi FL, Antivalle M, Benucci M, Fusaro E, et al. Safety and efficacy of switching from innovator to biosimilar infliximab in patients affected by spondyloarthritis. A 6-month observational study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.5115.
-
(2016)
European League Against Rheumatism
, vol.2016
-
-
Batticciotto, A.1
Parisi, S.2
Gobbi, F.L.3
Antivalle, M.4
Benucci, M.5
Fusaro, E.6
-
38
-
-
85052688496
-
Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study
-
Washington DC, USA: Arthritis Rheumatol
-
Batticciotto A, Antivalle M, Gobbi FL, Parisi S, Talotta R, Varisco V, et al. Safety and efficacy of switching from originator to CT-P13 infliximab biosimilar in patients affected by spondyloarthritis. A 6-month observational study. American College of Rheumatology 2016; Washington DC, USA: Arthritis Rheumatol. 2016.
-
(2016)
American College of Rheumatology
, vol.2016
-
-
Batticciotto, A.1
Antivalle, M.2
Gobbi, F.L.3
Parisi, S.4
Talotta, R.5
Varisco, V.6
-
39
-
-
85021240270
-
Clinical experience with infliximab biosimilar—switch from Remicade
-
Rome, Italy; Ann Rheum Dis
-
Sokka T, Kautiainen H. Clinical experience with infliximab biosimilar—switch from Remicade. European League Against Rheumatism 2015; Rome, Italy; Ann Rheum Dis: 2015. doi:10.1136/annrheumdis-2015-eular.2151.
-
(2015)
European League Against Rheumatism
, vol.2015
-
-
Sokka, T.1
Kautiainen, H.2
-
40
-
-
84946601256
-
Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
-
COI: 1:CAS:528:DC%2BC2MXhvVSltL3N, PID: 26549204
-
Nikiphorou E, Kautiainen H, Hannonen P, Asikainen J, Kokko A, Rannio T, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83. doi:10.1517/14712598.2015.1103733.
-
(2015)
Expert Opin Biol Ther
, vol.15
, pp. 1677-1683
-
-
Nikiphorou, E.1
Kautiainen, H.2
Hannonen, P.3
Asikainen, J.4
Kokko, A.5
Rannio, T.6
-
41
-
-
85016146498
-
Long term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product
-
London: UK; Ann Rheum Dis
-
Abdalla A, Byrne NE, Conway R, Walsh T, Mannion G, Hanly M, et al. Long term safety and efficacy of biosimilar infliximab among patients with inflammatory arthritis switched from reference product. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.2147/OARRR.S124975.
-
(2016)
European League Against Rheumatism
, vol.2016
-
-
Abdalla, A.1
Byrne, N.E.2
Conway, R.3
Walsh, T.4
Mannion, G.5
Hanly, M.6
-
42
-
-
85055728078
-
Infliximab biosimilars—switching Remicade to Remsima in routine care: patient acceptability and early outcome data
-
Annual Meeting; Glasgow, UK; Rheumatology (Oxford
-
Malaiya R, McKee Z, Kiely P. Infliximab biosimilars—switching Remicade to Remsima in routine care: patient acceptability and early outcome data. British Society for Rheumatology 2016 Annual Meeting; Glasgow, UK; Rheumatology (Oxford): 2016.
-
(2016)
British Society for Rheumatology
, vol.2016
-
-
Malaiya, R.1
McKee, Z.2
Kiely, P.3
-
43
-
-
85021243072
-
Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice
-
Washington DC: USA
-
Tweehuysen L, van den Bemt BJF, van Ingen IL, de Jong AJL, van der Laan WH, van den Hoogen FHJ, et al. Clinical and immunogenicity outcomes after switching treatment from innovator infliximab to biosimilar infliximab in rheumatic diseases in daily clinical practice. American College of Rheumatology 2016; Washington DC, USA: 2016.
-
(2016)
American College of Rheumatology
, vol.2016
-
-
Tweehuysen, L.1
van den Bemt, B.J.F.2
van Ingen, I.L.3
de Jong, A.J.L.4
van der Laan, W.H.5
van den Hoogen, F.H.J.6
-
44
-
-
85021225235
-
Switching from Remicade(R) to Remsima(R) is safe and feasible: a prospective, open-label study
-
Buer LC, Moum BA, Cvancarova M, Warren DJ, Medhus AW, Hoivik ML. Switching from Remicade(R) to Remsima(R) is safe and feasible: a prospective, open-label study. J Crohns Colitis. 2017;11:297–304.
-
(2017)
J Crohns Colitis
, vol.11
, pp. 297-304
-
-
Buer, L.C.1
Moum, B.A.2
Cvancarova, M.3
Warren, D.J.4
Medhus, A.W.5
Hoivik, M.L.6
-
45
-
-
85021195001
-
Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Bettey M, Downey L, Underhill C, Callaghan J, Rush M, Ahmed I, et al. Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
-
(2016)
The Netherlands
-
-
Bettey, M.1
Downey, L.2
Underhill, C.3
Callaghan, J.4
Rush, M.5
Ahmed, I.6
-
46
-
-
84940081554
-
Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study
-
COI: 1:CAS:528:DC%2BC2MXhvFCqtr%2FF, PID: 25974251
-
Jung YS, Park DI, Kim YH, Lee JH, Seo PJ, Cheon JH, et al. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: a retrospective multicenter study. J Gastroenterol Hepatol. 2015;30:1705–12. doi:10.1111/jgh.12997.
-
(2015)
J Gastroenterol Hepatol
, vol.30
, pp. 1705-1712
-
-
Jung, Y.S.1
Park, D.I.2
Kim, Y.H.3
Lee, J.H.4
Seo, P.J.5
Cheon, J.H.6
-
47
-
-
85021242110
-
-
Spain, J Crohns Colitis
-
Jung YS, Park DI, Kim YH, Seo PJ, Kim JW, Kang HW. Efficacy and safety of infliximab’s biosimilar (REMSIMA) for IBD. 10th Congress of the European Crohn’s and Colitis Organisation; Barcelona, Spain; J Crohns Colitis: 2015.
-
(2015)
Park DI, Kim YH, Seo PJ, Kim JW, Kang HW. Efficacy and safety of infliximab’s biosimilar (REMSIMA) for IBD. 10th Congress of the European Crohn’s and Colitis Organisation; Barcelona
-
-
-
48
-
-
85021195038
-
Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Smits L, Derikx L, Drenth J, de Jong D, van Esch A, Hoentjen F. Elective switching from Remicade® to biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
-
(2016)
The Netherlands
-
-
Smits, L.1
Derikx, L.2
Drenth, J.3
de Jong, D.4
van Esch, A.5
Hoentjen, F.6
-
49
-
-
85012255168
-
Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study
-
PID: 27095751
-
Smits LJT, Derikx LAAP, de Jong DJ, Boshuizen RS, van Esch AAJ, Drenth JPH, et al. Clinical outcomes following a switch from Remicade® to the biosimilar CT-P13 in inflammatory bowel disease patients: a prospective observational cohort study. J Crohns Colitis. 2016;10:1287–93.
-
(2016)
J Crohns Colitis
, vol.10
, pp. 1287-1293
-
-
Smits, L.J.T.1
Derikx, L.A.A.P.2
de Jong, D.J.3
Boshuizen, R.S.4
van Esch, A.A.J.5
Drenth, J.P.H.6
-
50
-
-
85021234656
-
Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Guerra Veloz MF, Argüelles Arias F, Perea Amarillo R, Castro Laria L, Maldonado Pérez MB, Benítez Roldán A, et al. Safety and efficacy of infliximab biosimilar (Remsima©) in Crohn’s disease patients in clinical practice: results after 6 months of treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016a.
-
(2016)
The Netherlands
-
-
Guerra Veloz, M.F.1
Argüelles Arias, F.2
Perea Amarillo, R.3
Castro Laria, L.4
Maldonado Pérez, M.B.5
Benítez Roldán, A.6
-
51
-
-
85021202424
-
Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Kolar M, Duricová D, Brotlik M, Hruba V, Machkova N, Mitrova K, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
-
(2016)
The Netherlands
-
-
Kolar, M.1
Duricová, D.2
Brotlik, M.3
Hruba, V.4
Machkova, N.5
Mitrova, K.6
-
52
-
-
85021206753
-
Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe—one-year follow-up. United European Gastroenterology Week; Vienna
-
Kolar M, Duricová D, Bortlik M, Hruba V, Machkova N, Mitrova K, et al. Switching of patients with inflammatory bowel disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe—one-year follow-up. United European Gastroenterology Week; Vienna, Austria; United European Gastroenterol J: 2016.
-
(2016)
Austria; United European Gastroenterol J
-
-
Kolar, M.1
Duricová, D.2
Bortlik, M.3
Hruba, V.4
Machkova, N.5
Mitrova, K.6
-
53
-
-
85021234656
-
Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Guerra Veloz MF, Argüelles Arias F, Perea Amarillo R, Castro Laria L, Maldonado Pérez MB, Benítez Roldán A, et al. Safety and efficacy of infliximab biosimilar (Remsima©) in ulcerative colitis disease patients in clinical practice: results after 6-months treatment. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016b.
-
(2016)
The Netherlands
-
-
Guerra Veloz, M.F.1
Argüelles Arias, F.2
Perea Amarillo, R.3
Castro Laria, L.4
Maldonado Pérez, M.B.5
Benítez Roldán, A.6
-
54
-
-
85021202600
-
-
Barcelona, Spain
-
Jarzebicka D, Banaszkiewicz A, Plocek A, Sieczkowska J, Gawronska A, Toporowska-Kowalska E, et al. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 10th Congress of the European Crohn’s and Colitis Organisation; Barcelona, Spain: 2015.
-
(2015)
Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 10th Congress of the European Crohn’s and Colitis Organisation
-
-
Jarzebicka, D.1
Banaszkiewicz, A.2
Plocek, A.3
Sieczkowska, J.4
Gawronska, A.5
Toporowska-Kowalska, E.6
-
55
-
-
84997758657
-
Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 46th Annual Digestive Disease Week; Washington DC
-
Kierkus J. Preliminary assessment of efficacy and safety of switching between originator and biosimilar infliximab in paediatric Crohn disease patients. 46th Annual Digestive Disease Week; Washington DC, USA; Gastroenterology: 2015. doi:10.1016/S0016-5085(15)32670-6.
-
(2015)
USA; Gastroenterology
-
-
Kierkus, J.1
-
56
-
-
85011663828
-
Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease
-
COI: 1:STN:280:DC%2BC28rmtlOjtw%3D%3D
-
Sieczkowska J, Jarzebicka D, Banaszkiewicz A, Plocek A, Gawronska A, Toporowska-Kowalska E, et al. Switching between infliximab originator and biosimilar in paediatric patients with inflammatory bowel disease. Prelim Observ J Crohns Colitis. 2016;10:127–32.
-
(2016)
Prelim Observ J Crohns Colitis
, vol.10
, pp. 127-132
-
-
Sieczkowska, J.1
Jarzebicka, D.2
Banaszkiewicz, A.3
Plocek, A.4
Gawronska, A.5
Toporowska-Kowalska, E.6
-
57
-
-
85021233283
-
-
Amsterdam, The Netherlands
-
Sieczkowska J, Jarzebicka D, Oracz G, Meglicka M, Dadalski M, Kierkus J. Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn’s disease. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016. doi:10.1093/ecco-jcc/jjw019.736.
-
(2016)
Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn’s disease. 11th Congress of the European Crohn’s and Colitis Organisation
-
-
Sieczkowska, J.1
Jarzebicka, D.2
Oracz, G.3
Meglicka, M.4
Dadalski, M.5
Kierkus, J.6
-
58
-
-
85021234169
-
Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Hlavaty T, Krajcovicova A, Sturdik I, Letkovsky J, Koller T, Toth J, et al. Biosimilar infliximab CT-P13 treatment in patients with inflammatory bowel diseases: a 1-year, single-centre retrospective study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
-
(2016)
The Netherlands
-
-
Hlavaty, T.1
Krajcovicova, A.2
Sturdik, I.3
Letkovsky, J.4
Koller, T.5
Toth, J.6
-
59
-
-
85021243564
-
-
Copenhagen: Denmark; J Crohns Colitis
-
Kang HW, Lim YJ, Kim JH, Kang YS. An experience of anti-TNF biosimilar, CT-P13 use: clinical efficacy, safety and interchangeability in inflammatory bowel disease; a pilot study. 9th Congress of the European Crohn’s and Colitis Organisation; Copenhagen, Denmark; J Crohns Colitis: 2014.
-
(2014)
An experience of anti-TNF biosimilar, CT-P13 use: clinical efficacy, safety and interchangeability in inflammatory bowel disease; a pilot study. 9th Congress of the European Crohn’s and Colitis Organisation
-
-
Kang, H.W.1
Lim, Y.J.2
Kim, J.H.3
Kang, Y.S.4
-
60
-
-
84934294253
-
Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series
-
COI: 1:CAS:528:DC%2BC2cXhvVamsr3J, PID: 25326115
-
Kang YS, Moon HH, Lee SE, Lim YJ, Kang HW. Clinical experience of the use of CT-P13, a biosimilar to infliximab in patients with inflammatory bowel disease: a case series. Dig Dis Sci. 2015;60:951–6. doi:10.1007/s10620-014-3392-z.
-
(2015)
Dig Dis Sci
, vol.60
, pp. 951-956
-
-
Kang, Y.S.1
Moon, H.H.2
Lee, S.E.3
Lim, Y.J.4
Kang, H.W.5
-
61
-
-
85021242056
-
What future for biosimilars in inflammatory bowel diseases?
-
National Congress; Palermo, Italy
-
Armuzzi A. What future for biosimilars in inflammatory bowel diseases? The Italian Group for the study of Inflammatory Bowel Disease VII National Congress; Palermo, Italy: 2015.
-
(2015)
The Italian Group for the study of Inflammatory Bowel Disease
, vol.7
-
-
Armuzzi, A.1
-
62
-
-
85021231286
-
Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Fiorino G, Manetti N, Variola A, Bossa F, Rizzuto G, Guidi L, et al. Prospective observational study on inflammatory bowel disease patients treated with infliximab biosimilars: preliminary results of the PROSIT-BIO cohort of the IG-IBD. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016. doi:10.1097/MIB.0000000000000995.
-
(2016)
The Netherlands
-
-
Fiorino, G.1
Manetti, N.2
Variola, A.3
Bossa, F.4
Rizzuto, G.5
Guidi, L.6
-
63
-
-
84942325078
-
Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea
-
Park SH, Kim YH, Lee JH, Kwon HJ, Lee SH, Park DI, et al. Post-marketing study of biosimilar infliximab (CT-P13) to evaluate its safety and efficacy in Korea. Exp Rev Gastroenterol Hepatol. 2015;9(Suppl 1):35–44.
-
(2015)
Exp Rev Gastroenterol Hepatol
, vol.9
, pp. 35-44
-
-
Park, S.H.1
Kim, Y.H.2
Lee, J.H.3
Kwon, H.J.4
Lee, S.H.5
Park, D.I.6
-
64
-
-
84995578185
-
The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis
-
COI: 1:CAS:528:DC%2BC28Xht1ygsr7O, PID: 27473452
-
Dapavo PMD, Vujic IMD, Fierro MTMD, Quaglino PMD, Sanlorenzo MMD. The infliximab biosimilar in the treatment of moderate to severe plaque psoriasis. J Am Acad Dermatol. 2016;75:736–9. doi:10.1016/j.jaad.2016.04.068.
-
(2016)
J Am Acad Dermatol
, vol.75
, pp. 736-739
-
-
Dapavo, P.M.D.1
Vujic, I.M.D.2
Fierro, M.T.M.D.3
Quaglino, P.M.D.4
Sanlorenzo, M.M.D.5
-
65
-
-
85011398033
-
Biosimilar infliximab (CT-P13) is not inferior to originator Infliximab: results from the 52-week randomized NOR-SWITCH trial. United European Gastroenterology Week; Vienna, Austria
-
The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching
-
• Jørgensen K, Olsen I, Goll G, Lorentzen M, Bolstad N, Haavardsholm E, et al. Biosimilar infliximab (CT-P13) is not inferior to originator Infliximab: results from the 52-week randomized NOR-SWITCH trial. United European Gastroenterology Week; Vienna, Austria; United European Gastroenterol J: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
United European Gastroenterol J
-
-
Jørgensen, K.1
Olsen, I.2
Goll, G.3
Lorentzen, M.4
Bolstad, N.5
Haavardsholm, E.6
-
66
-
-
85021195033
-
Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway
-
Washington DC, USA; Arthritis Rheumatol: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching
-
• Goll GL, Olsen IC, Jorgensen KK, Lorentzen M, Bolstad N, Haavardsholm EA, et al. Biosimilar infliximab (CT-P13) is not inferior to originator infliximab: results from a 52-week randomized switch trial in Norway. American College of Rheumatology 2016; Washington DC, USA; Arthritis Rheumatol: 2016. The NOR-SWITCH study is the largest clinical trial of switching from infliximab to CT-P13 and includes patients from multiple indications. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
American College of Rheumatology
-
-
Goll, G.L.1
Olsen, I.C.2
Jorgensen, K.K.3
Lorentzen, M.4
Bolstad, N.5
Haavardsholm, E.A.6
-
67
-
-
84946601256
-
Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data
-
Expert Opin Biol Ther. 2016;16:1311-2
-
Gentileschi S, Barreca C, Bellisai F, Biasi G, Brizi MG, De Stefano R, et al. Switch from infliximab to infliximab biosimilar: efficacy and safety in a cohort of patients with different rheumatic diseases: response to: Nikiphorou E, Kautiainen H, Hannonen P, et al. Clinical effectiveness of CT-P13 (infliximab biosimilar) used as a switch from Remicade (infliximab) in patients with established rheumatic disease. Report of clinical experience based on prospective observational data. Expert Opin Biol Ther. 2015;15:1677–83. Expert Opin Biol Ther. 2016;16:1311-2
-
(2015)
Expert Opin Biol Ther
, vol.15
, pp. 1677-1683
-
-
Gentileschi, S.1
Barreca, C.2
Bellisai, F.3
Biasi, G.4
Brizi, M.G.5
De Stefano, R.6
-
72
-
-
85021242075
-
An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD)
-
Accessed 22 Mar
-
EU Clinical Trials Register. An open-label, multicentre, phase IV study to investigate the infliximab serum concentration of Remsima™ (infliximab biosimilar) after switching from Remicade (infliximab) in subjects with Crohn’s Disease (CD), Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission. http://www.clinicaltrialsregister.eu/ctr-search/trial/2014-004904-31/NL. Accessed 22 Mar 2016.
-
(2016)
Ulcerative Colitis (UC) or Rheumatoid Arthritis (RA) in stable remission
-
-
-
73
-
-
85017017931
-
Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study
-
London, UK; Ann Rheum Dis: 2016. doi:. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching
-
• Smolen J, Choe JY, Prodanovic N, Niebrzdowski J, Staykov I, Dokoupilova E, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing infliximab reference product in patients with rheumatoid arthritis: results of phase III transition study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.3122. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
European League Against Rheumatism
-
-
Smolen, J.1
Choe, J.Y.2
Prodanovic, N.3
Niebrzdowski, J.4
Staykov, I.5
Dokoupilova, E.6
-
74
-
-
85021212361
-
Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing reference infliximab (Remicade®) in patients with rheumatoid arthritis: results of phase III transition study
-
Washington DC, USA: 2016. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching
-
• Smolen JS, Choe JY, Prodanovic N, Niebrzydowski J, Staykov I, Dokoupilova E, et al. Comparable safety and immunogenicity and sustained efficacy after transition to SB2 (an infliximab biosimilar) vs ongoing reference infliximab (Remicade®) in patients with rheumatoid arthritis: results of phase III transition study. American College of Rheumatology 2016; Washington DC, USA: 2016. Only published study to date of switching from infliximab to SB2. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
American College of Rheumatology
-
-
Smolen, J.S.1
Choe, J.Y.2
Prodanovic, N.3
Niebrzydowski, J.4
Staykov, I.5
Dokoupilova, E.6
-
75
-
-
85021191319
-
Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Hamanaka S, Nakagawa T, Koseki H, Sakurai T, Taida T, Okimoto K, et al. Infliximab biosimilar in the treatment of inflammatory bowel disease: a Japanese single-cohort observational study. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016.
-
(2016)
The Netherlands
-
-
Hamanaka, S.1
Nakagawa, T.2
Koseki, H.3
Sakurai, T.4
Taida, T.5
Okimoto, K.6
-
76
-
-
85021232454
-
Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam
-
Díaz Hernández L, Rodríguez González GE, Vela González M, Tardillo Marín CA, Rodríguez Díaz CY, Arranz Hernández L et al. Efficacy and safety of switching between originator and biosimilar infliximab in patients with inflammatory bowel disease in practical clinic: results to 6 months. 11th Congress of the European Crohn’s and Colitis Organisation; Amsterdam, The Netherlands: 2016. doi:10.1093/ecco-jcc/jjw019.568.
-
(2016)
The Netherlands
-
-
Díaz Hernández, L.1
Rodríguez González, G.E.2
Vela González, M.3
Tardillo Marín, C.A.4
Rodríguez Díaz, C.Y.5
Arranz Hernández, L.6
-
78
-
-
85021210331
-
Longterm safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4
-
London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
-
• Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Stasiuk B, et al. Longterm safety and efficacy of SB4 (etanercept biosimilar) in patients with rheumatoid arthritis: comparison between continuing SB4 and switching from etanercept reference product to SB4. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
European League Against Rheumatism
-
-
Emery, P.1
Vencovský, J.2
Sylwestrzak, A.3
Leszczynski, P.4
Porawska, W.5
Stasiuk, B.6
-
79
-
-
85021191189
-
Additional efficacy results of SB4 (etanercept biosimilar) up to week 100: comparison between continuing SB4 and switching from reference etanercept (Enbrel®) to SB4
-
Washington DC, USA: 2016. Ann Rheum Dis: 2016;75(Suppl2):236. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
-
• Emery P, Vencovský J, Sylwestrzak A, Leszczynski P, Porawska W, Stasiuk B, et al. Additional efficacy results of SB4 (etanercept biosimilar) up to week 100: comparison between continuing SB4 and switching from reference etanercept (Enbrel®) to SB4. American College of Rheumatology 2016; Washington DC, USA: 2016. Ann Rheum Dis: 2016;75(Suppl2):236. Only published study to date of switching from etanercept to SB4 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
American College of Rheumatology
-
-
Emery, P.1
Vencovský, J.2
Sylwestrzak, A.3
Leszczynski, P.4
Porawska, W.5
Stasiuk, B.6
-
80
-
-
84976601138
-
A randomised Phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel(R)) in healthy subjects
-
Lee Y, Shin D, Kim Y, Kang J, Gauliard A, Fuhr R. A randomised Phase l pharmacokinetic study comparing SB4 and etanercept reference product (Enbrel(R)) in healthy subjects. Br J Clin Pharmacol. 2016;82:64–73. doi:10.1111/bcp.12929.
-
(2016)
Br J Clin Pharmacol
, vol.82
, pp. 64-73
-
-
Lee, Y.1
Shin, D.2
Kim, Y.3
Kang, J.4
Gauliard, A.5
Fuhr, R.6
-
81
-
-
85021242448
-
A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects
-
Rome, Italy; Ann Rheum Dis
-
Lee YJ, Shin D, Kim Y, Kang JW, Fuhr R, Gauliard A. A phase I pharmacokinetic study comparing SB4, an etanercept biosimilar, and etanercept reference product (Enbrel®) in healthy male subjects. European League Against Rheumatism 2015; Rome, Italy; Ann Rheum Dis: 2015.
-
(2015)
European League Against Rheumatism
, vol.2015
-
-
Lee, Y.J.1
Shin, D.2
Kim, Y.3
Kang, J.W.4
Fuhr, R.5
Gauliard, A.6
-
83
-
-
85014009195
-
The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis
-
Only published study to date of switching from etanercept to GP2015 in patients. Interchangeability design with 2 control treatment arms allows effect of multiple switching to be assessed. This study also provides important efficacy, safety and immunogenicity data on switching
-
• Griffiths CE, Thaci D, Gerdes S, Arenberger P, Pulka G, Kingo K, et al. The EGALITY study: a confirmatory, randomised, double-blind study comparing the efficacy, safety and immunogenicity of GP2015, a proposed etanercept biosimilar, versus the originator product in patients with moderate to severe chronic plaque-type psoriasis. Br J Dermatol. 2017;176:928–38. Only published study to date of switching from etanercept to GP2015 in patients. Interchangeability design with 2 control treatment arms allows effect of multiple switching to be assessed. This study also provides important efficacy, safety and immunogenicity data on switching.
-
(2017)
Br J Dermatol
, vol.176
, pp. 928-938
-
-
Griffiths, C.E.1
Thaci, D.2
Gerdes, S.3
Arenberger, P.4
Pulka, G.5
Kingo, K.6
-
84
-
-
85021220815
-
Pharmacokinetics and safety of GP2015, a proposed etanercept biosimilar, and etanercept originator product in healthy male subjects: a randomised twoway crossover study
-
London: UK; Ann Rheum Dis
-
Afonso M, Sanguino Heinrich S, Poetzl J, Woehling H. Pharmacokinetics and safety of GP2015, a proposed etanercept biosimilar, and etanercept originator product in healthy male subjects: a randomised twoway crossover study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. doi:10.1136/annrheumdis-2016-eular.1422.
-
(2016)
European League Against Rheumatism
, vol.2016
-
-
Afonso, M.1
Sanguino Heinrich, S.2
Poetzl, J.3
Woehling, H.4
-
86
-
-
84860619510
-
Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel(R)): a double-blind, single-dose, crossover study in healthy volunteers
-
COI: 1:CAS:528:DC%2BC38XhtVSqtLzN, PID: 22515513
-
Yi S, Kim SE, Park MK, Yoon SH, Cho JY, Lim KS, et al. Comparative pharmacokinetics of HD203, a biosimilar of etanercept, with marketed etanercept (Enbrel(R)): a double-blind, single-dose, crossover study in healthy volunteers. BioDrugs. 2012;26:177–84. doi:10.2165/11631860-000000000-00000.
-
(2012)
BioDrugs
, vol.26
, pp. 177-184
-
-
Yi, S.1
Kim, S.E.2
Park, M.K.3
Yoon, S.H.4
Cho, J.Y.5
Lim, K.S.6
-
88
-
-
85021233226
-
LBEC0101, an etanercept biosimilar, showed comparable tolerability and pharmacokinetic profiles to those of etanercept in healthy male volunteers. 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia
-
Chung H, Ahn L, Choi Y, Shin S, Jang I, Yu K, et al. LBEC0101, an etanercept biosimilar, showed comparable tolerability and pharmacokinetic profiles to those of etanercept in healthy male volunteers. 115th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia, USA; Clin Pharmacol Ther. 95:S5–S6.
-
USA; Clin Pharmacol Ther
, vol.95
, pp. S5-S6
-
-
Chung, H.1
Ahn, L.2
Choi, Y.3
Shin, S.4
Jang, I.5
Yu, K.6
-
91
-
-
85021211627
-
Comparative pharmacokinetics/tolerability of TuNEX and Enbrel® in healthy Korean volunteers. 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia
-
Gu N, Kim BR, Kim BH, Kim JW, Song DH, Shin SG, et al. Comparative pharmacokinetics/tolerability of TuNEX and Enbrel® in healthy Korean volunteers. 111th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics; Atlanta, Georgia, USA; Clin Pharmacol Ther: 2010.
-
(2010)
USA; Clin Pharmacol Ther
-
-
Gu, N.1
Kim, B.R.2
Kim, B.H.3
Kim, J.W.4
Song, D.H.5
Shin, S.G.6
-
92
-
-
83455201580
-
Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers
-
COI: 1:CAS:528:DC%2BC3MXhs1CjtLvF, PID: 22088414
-
Gu N, Yi S, Kim TE, Kim J, Shin SG, Jang IJ, et al. Comparative pharmacokinetics and tolerability of branded etanercept (25 mg) and its biosimilar (25 mg): a randomized, open-label, single-dose, two-sequence, crossover study in healthy Korean male volunteers. Clin Ther. 2011;33:2029–37. doi:10.1016/j.clinthera.2011.10.022.
-
(2011)
Clin Ther
, vol.33
, pp. 2029-2037
-
-
Gu, N.1
Yi, S.2
Kim, T.E.3
Kim, J.4
Shin, S.G.5
Jang, I.J.6
-
93
-
-
85021212378
-
ABP 501 long-term safety/efficacy: interim results from an open-label extension study
-
Washington DC, USA; 2016;68(suppl 10). Accessed 17 May 2017. Only published study to date of switching from adalimumab to ABP 501 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching
-
• Cohen S, Pablos JL, Zhang N, Rizzo W, Muller G, Padmanaban D, et al. ABP 501 long-term safety/efficacy: interim results from an open-label extension study. American College of Rheumatology 2016; Washington DC, USA; 2016;68(suppl 10). http://acrabstracts.org/abstract/abp-501-long-term-safetyefficacy-interim-results-from-an-open-label-extension-study/. Accessed 17 May 2017. Only published study to date of switching from adalimumab to ABP 501 in patients with RA. This study provides important efficacy, safety and immunogenicity data on switching.
-
(2016)
American College of Rheumatology
-
-
Cohen, S.1
Pablos, J.L.2
Zhang, N.3
Rizzo, W.4
Muller, G.5
Padmanaban, D.6
-
94
-
-
85021186601
-
Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. American Academy of Dermatology 74th Annual Meeting; Washington DC
-
Strober B, Foley P, Kaur P, Philipp S, Zhang N. Evaluation of efficacy and safety of ABP 501 in a phase 3 study in subjects with moderate to severe plaque psoriasis: 52-week results. American Academy of Dermatology 74th Annual Meeting; Washington DC, USA; J Am Acad Dermatol: 2016.
-
(2016)
USA; J Am Acad Dermatol
-
-
Strober, B.1
Foley, P.2
Kaur, P.3
Philipp, S.4
Zhang, N.5
-
95
-
-
85021211835
-
Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis. American Academy of Dermatology 74th Annual Meeting; Washington DC
-
Gooderham M, Constanzo A, Kaliaperumal A, Kaur P, Narbutt J, Spelman L, et al. Single transition from adalimumab to ABP 501: evaluation of immunogenicity in a phase 3 study in subjects with moderate to severe plaque psoriasis. American Academy of Dermatology 74th Annual Meeting; Washington DC, USA; J Am Acad Dermatol: 2016.
-
(2016)
USA; J Am Acad Dermatol
-
-
Gooderham, M.1
Constanzo, A.2
Kaliaperumal, A.3
Kaur, P.4
Narbutt, J.5
Spelman, L.6
-
96
-
-
85021240490
-
Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: result of phase III study
-
London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking
-
• Weinblatt M, Baranauskaite A, Niebrzydowski J, Dokoupilova E, Zielinska A, Sitek-Ziolkowska K, et al. Sustained efficacy and comparable safety and immunogenicity after transition to SB5 (an adalimumab biosimilar) vs continuation of the adalimumab reference product in patients with rheumatoid arthritis: result of phase III study. European League Against Rheumatism 2016; London, UK; Ann Rheum Dis: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking.
-
(2016)
European League Against Rheumatism
-
-
Weinblatt, M.1
Baranauskaite, A.2
Niebrzydowski, J.3
Dokoupilova, E.4
Zielinska, A.5
Sitek-Ziolkowska, K.6
-
97
-
-
85021238538
-
Efficacy after transition to SB5 from reference adalimumab (Humira®) vs. continuation of SB5 or reference adalimumab by antibodies developed after transition from a SB5 phase III study
-
Washington DC, USA: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking
-
• Genovese MC, Weinblatt M, Keystone EC, Baranauskaite A, Cheong SY, Ghil J. Efficacy after transition to SB5 from reference adalimumab (Humira®) vs. continuation of SB5 or reference adalimumab by antibodies developed after transition from a SB5 phase III study. American College of Rheumatology 2016; Washington DC, USA: 2016. Only published study to date of switching from adalimumab to SB5 in patients with RA. This study provides important immunogenicity data on switching, although efficacy and safety data are lacking.
-
(2016)
although efficacy and safety data are lackingAmerican College of Rheumatology
-
-
Genovese, M.C.1
Weinblatt, M.2
Keystone, E.C.3
Baranauskaite, A.4
Cheong, S.Y.5
Ghil, J.6
-
99
-
-
85013244232
-
Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks
-
Only published study to date of switching from rituximab to CT-P10 in patients with RA. This study provides important efficacy and safety data on switching, although immunogenicity data are lacking
-
• Yoo DH, Park W, Suh CH, Shim SC, Cons Molina F, Jeka S, et al. Efficacy and safety of switched CT-P10 from innovator rituximab compared to those of maintained CT-P10 in patients with rheumatoid arthritis up to 56 weeks. American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheumatol: 2015. Only published study to date of switching from rituximab to CT-P10 in patients with RA. This study provides important efficacy and safety data on switching, although immunogenicity data are lacking.
-
(2015)
American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheumatol
-
-
Yoo, D.H.1
Park, W.2
Suh, C.H.3
Shim, S.C.4
Cons Molina, F.5
Jeka, S.6
-
101
-
-
84962037330
-
A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study
-
Yoo DH, Racewicz A, Brzezicki J, Yatsyshyn R, Arteaga ET, Baranauskaite A, et al. A phase III randomized study to evaluate the efficacy and safety of CT-P13 compared with reference infliximab in patients with active rheumatoid arthritis: 54-week results from the PLANETRA study. Arthritis Res Ther. 2016;18:1–12.
-
(2016)
Arthritis Res Ther
, vol.18
, pp. 1-12
-
-
Yoo, D.H.1
Racewicz, A.2
Brzezicki, J.3
Yatsyshyn, R.4
Arteaga, E.T.5
Baranauskaite, A.6
-
102
-
-
84954568420
-
Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study
-
PID: 26795209
-
Park W, Yoo DH, Jaworski J, Brzezicki J, Gnylorybov A, Kadinov V, et al. Comparable long-term efficacy, as assessed by patient-reported outcomes, safety and pharmacokinetics, of CT-P13 and reference infliximab in patients with ankylosing spondylitis: 54-week results from the randomized, parallel-group PLANETAS study. Arthritis Res Ther. 2016;18:25.
-
(2016)
Arthritis Res Ther
, vol.18
, pp. 25
-
-
Park, W.1
Yoo, D.H.2
Jaworski, J.3
Brzezicki, J.4
Gnylorybov, A.5
Kadinov, V.6
-
103
-
-
84947032856
-
Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis
-
COI: 1:CAS:528:DC%2BC2MXhvV2ktLvK, PID: 25736355
-
Takeuchi T, Yamanaka H, Tanaka Y, Sakurai T, Saito K, Ohtsubo H, et al. Evaluation of the pharmacokinetic equivalence and 54-week efficacy and safety of CT-P13 and innovator infliximab in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2015;25:817–24. doi:10.3109/14397595.2015.1022297.
-
(2015)
Mod Rheumatol
, vol.25
, pp. 817-824
-
-
Takeuchi, T.1
Yamanaka, H.2
Tanaka, Y.3
Sakurai, T.4
Saito, K.5
Ohtsubo, H.6
-
104
-
-
84883746909
-
A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study
-
COI: 1:CAS:528:DC%2BC3sXhs1eis7nM, PID: 23687259
-
Park W, Hrycaj P, Jeka S, Kovalenko V, Lysenko G, Miranda P, et al. A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: the PLANETAS study. Ann Rheum Dis. 2013;72:1605–12. doi:10.1136/annrheumdis-2012-203091.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 1605-1612
-
-
Park, W.1
Hrycaj, P.2
Jeka, S.3
Kovalenko, V.4
Lysenko, G.5
Miranda, P.6
-
105
-
-
77953177072
-
A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis
-
PID: 20231198
-
Inman RD, Maksymowych WP. A double-blind, placebo-controlled trial of low dose infliximab in ankylosing spondylitis. J Rheumatol. 2010;37:1203–10. doi:10.3899/jrheum.091042.
-
(2010)
J Rheumatol
, vol.37
, pp. 1203-1210
-
-
Inman, R.D.1
Maksymowych, W.P.2
-
106
-
-
54949091496
-
Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period
-
COI: 1:CAS:528:DC%2BD1cXhtlKqsbzO, PID: 18759257
-
Braun J, Deodhar A, Dijkmans B, Geusens P, Sieper J, Williamson P, et al. Efficacy and safety of infliximab in patients with ankylosing spondylitis over a two-year period. Arthritis Rheum. 2008;59:1270–8. doi:10.1002/art.24001.
-
(2008)
Arthritis Rheum
, vol.59
, pp. 1270-1278
-
-
Braun, J.1
Deodhar, A.2
Dijkmans, B.3
Geusens, P.4
Sieper, J.5
Williamson, P.6
-
107
-
-
38149024172
-
Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment
-
COI: 1:CAS:528:DC%2BD1cXhslOjtr4%3D, PID: 18163509
-
Breban M, Ravaud P, Claudepierre P, Baron G, Henry YD, Hudry C, et al. Maintenance of infliximab treatment in ankylosing spondylitis: results of a one-year randomized controlled trial comparing systematic versus on-demand treatment. Arthritis Rheum. 2008;58:88–97. doi:10.1002/art.23167.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 88-97
-
-
Breban, M.1
Ravaud, P.2
Claudepierre, P.3
Baron, G.4
Henry, Y.D.5
Hudry, C.6
-
108
-
-
33745600393
-
Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up
-
COI: 1:CAS:528:DC%2BD28Xmt1Wrsrc%3D
-
Gossec L, Le Henanff A, Breban M, Vignon E, Claudepierre P, Devauchelle V, et al. Continuation of treatment with infliximab in ankylosing spondylitis: 2-yr open follow-up. Rheumatology (Oxford). 2006;45:859–62. doi:10.1093/rheumatology/kel015.
-
(2006)
Rheumatology (Oxford)
, vol.45
, pp. 859-862
-
-
Gossec, L.1
Le Henanff, A.2
Breban, M.3
Vignon, E.4
Claudepierre, P.5
Devauchelle, V.6
-
109
-
-
19944432148
-
Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis
-
COI: 1:CAS:528:DC%2BD2MXhvFyrtbk%3D, PID: 15388511
-
Braun J, Brandt J, Listing J, Zink A, Alten R, Burmester G, et al. Two year maintenance of efficacy and safety of infliximab in the treatment of ankylosing spondylitis. Ann Rheum Dis. 2005;64:229–34.
-
(2005)
Ann Rheum Dis
, vol.64
, pp. 229-234
-
-
Braun, J.1
Brandt, J.2
Listing, J.3
Zink, A.4
Alten, R.5
Burmester, G.6
-
110
-
-
0345490895
-
Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study
-
COI: 1:STN:280:DC%2BD3srmsVKgsw%3D%3D, PID: 14644863
-
Temekonidis TI, Alamanos Y, Nikas SN, Bougias DV, Georgiadis AN, Voulgari PV, et al. Infliximab therapy in patients with ankylosing spondylitis: an open label 12 month study. Ann Rheum Dis. 2003;62:1218–20.
-
(2003)
Ann Rheum Dis
, vol.62
, pp. 1218-1220
-
-
Temekonidis, T.I.1
Alamanos, Y.2
Nikas, S.N.3
Bougias, D.V.4
Georgiadis, A.N.5
Voulgari, P.V.6
-
111
-
-
85021206793
-
A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel®) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results)
-
San Francisco, California, USA; Arthritis Rheum
-
Vencovský J, Sylwestrzak A, Leszczyński P, Porawska W, Baranauskaite A, Tseluyko V, et al. A phase III, randomized, double-blind clinical study comparing SB4, an etanercept biosimilar, with etanercept reference product (Enbrel®) in patients with moderate to severe rheumatoid arthritis despite methotrexate therapy (52-week results). American College of Rheumatology 2015; San Francisco, California, USA; Arthritis Rheum: 2015. doi:10.1136/annrheumdis-2015-eular.1220.
-
(2015)
American College of Rheumatology
, vol.2015
-
-
Vencovský, J.1
Sylwestrzak, A.2
Leszczyński, P.3
Porawska, W.4
Baranauskaite, A.5
Tseluyko, V.6
-
112
-
-
84978765827
-
Difference between enbrel and benepali treatment groups in ‘hepatobiliary disorders’
-
PID: 27432354
-
Scheinberg M, Azevedo V. Difference between enbrel and benepali treatment groups in ‘hepatobiliary disorders’. Ann Rheum Dis. 2016;75:e64. doi:10.1136/annrheumdis-2016-210101.
-
(2016)
Ann Rheum Dis
, vol.75
-
-
Scheinberg, M.1
Azevedo, V.2
-
113
-
-
84990246948
-
Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo
-
Emery P, Vencovský J, Ghil J, Cheong SY, Rho YH. Difference between SB4 and reference etanercept in the hepatobiliary disorders not considered to be caused by SB4: response to letter by Scheinberg and Azevedo. Ann Rheum Dis. 2016;75:e65. doi:10.1136/annrheumdis-2016-210127.
-
(2016)
Ann Rheum Dis
, vol.e65
, pp. 75
-
-
Emery, P.1
Vencovský, J.2
Ghil, J.3
Cheong, S.Y.4
Rho, Y.H.5
-
114
-
-
85021200743
-
A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis
-
San Diego, California, USA
-
Yoo DH, Park W, Jeka S, Cons Molina F, Hrycaj P, Wiland P, et al. A randomized, controlled, multicenter, 2-arm, parallel-group, double-blind study to demonstrate the equivalence of CT-P10 to innovator rituximab with respect to pharmacokinetic profile in patients with rheumatoid arthritis. American College of Rheumatology 2013; San Diego, California, USA: 2013.
-
(2013)
American College of Rheumatology
, vol.2013
-
-
Yoo, D.H.1
Park, W.2
Jeka, S.3
Cons Molina, F.4
Hrycaj, P.5
Wiland, P.6
-
115
-
-
85012855515
-
The economic implications of biosimilars
-
PID: 26788809
-
Singh SC, Bagnato KM. The economic implications of biosimilars. Am J Manag Care. 2015;21:s331–s40.
-
(2015)
Am J Manag Care
, vol.21
, pp. s331-s340
-
-
Singh, S.C.1
Bagnato, K.M.2
-
116
-
-
84893044719
-
Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars?
-
COI: 1:CAS:528:DC%2BC2cXisFOlsQ%3D%3D, PID: 24114449
-
Lee H. Is extrapolation of the safety and efficacy data in one indication to another appropriate for biosimilars? AAPS J. 2014;16:22–6. doi:10.1208/s12248-013-9534-y.
-
(2014)
AAPS J
, vol.16
, pp. 22-26
-
-
Lee, H.1
-
117
-
-
33847765006
-
The use of therapeutic interchange for biologic therapies
-
Flood J, Mihalik C, Fleming RR, Strober BE, Zucker DR, Burgoyne DS. The use of therapeutic interchange for biologic therapies. Manag Care. 2007;16:51–62.
-
(2007)
Manag Care
, vol.16
, pp. 51-62
-
-
Flood, J.1
Mihalik, C.2
Fleming, R.R.3
Strober, B.E.4
Zucker, D.R.5
Burgoyne, D.S.6
-
118
-
-
85021186693
-
inVentiv Health Clinical
-
Accessed 10 Mar
-
inVentiv Health Clinical. Elderly representation in clinical trials: not a gray area. http://www.inventivhealthclinical.com/resource-library-white-papers.htm. Accessed 10 Mar 2016.
-
(2016)
Elderly representation in clinical trials: not a gray area
-
-
-
119
-
-
84864742645
-
-
The challenges of switching medicines, Stockholm Network
-
Chu R, Torstensson D, Pugatch M. Patient safety and comfort. The challenges of switching medicines. Stockholm Network. 2010. http://www.patients-rights.org/uploadimages/Patient_Safety_and_Comfort_The_Challenges_of_Switching.pdf. Accessed 31 Mar 2016.
-
(2010)
Patient safety and comfort
-
-
Chu, R.1
Torstensson, D.2
Pugatch, M.3
|